NDA 019123 · Upsher Smith Labs
Klor-Con
Potassium Chloride · Oral
Last checked: Nov 20, 2026Latest source record: Apr 30, 2018 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1986
Apr 17, 1986
Approved uses
2
Original approval plus efficacy supplements
Registered trials
9,299
2,122 Phase 3, 968 recruiting
FAERS reports
110,575
80,896 serious, 15,665 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jan 1, 2026.
Potassium chloride extended-release is indicated for the treatment and prophylaxis of hypokalemia with or without metabolic alkalosis, in patients for whom dietary management with potassium-rich foods or diuretic dose reduction is insufficient. Potassium chloride extended-release is a potassium salt, indicated for the treatment and prophylaxis of hypokalemia with or without metabolic alkalosis in patients for whom dietary management with potassium-rich foods or diuretic dose reduction is insufficient. ( 1 )
Mechanism: The potassium ion is the principal intracellular cation of most body tissues. Potassium ions participate in a number of essential physiological processes including the maintenance of intracellular tonicity, the transmission of nerve impulses, the contraction of cardiac, skeletal and smooth muscle and the maintenance of normal renal function. The intracellular concentration of potassium is approximately 150 mEq to 160 mEq per liter. The normal adult plasma concentration is 3.5 mEq to 5 mEq per liter. An active ion transport system maintains this gradient across the plasma membrane. Potassium...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 26, 1992 Supplement 8 · Efficacy
- Apr 17, 1986 Original approval · Type 5 - New Formulation or New Manufacturer Review
2 products under this application
- KLOR-CON · POTASSIUM CHLORIDE 10MEQ · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB2
- KLOR-CON · POTASSIUM CHLORIDE 8MEQ · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB2
Clinical trials
Interventional ClinicalTrials.gov studies with "Chloride" as an intervention, any sponsor and status, largest first.
- Introduction of Cholera Vaccine in BangladeshPivotal-lookingCompleted
International Centre for Diarrhoeal Disease Research, BangladeshAcademic, hospital or other
NCT01339845 · 240,000 participants · Start Sep 2009 · Primary completion Dec 2016
Drug: ShanChol · For: Cholera
Sites: Dhaka, Bangladesh
- Vellore Typhoid Vaccine Impact TrialPivotal-lookingCompleted
Christian Medical College, Vellore, IndiaAcademic, hospital or other
NCT05500482 · 72,400 participants · Start May 1, 2023 · Primary completion Jan 31, 2026
Drug: Typhoid conjugate Vaccine · For: Typhoid Fever
Sites: Vellore, India
- Randomised Evaluation of COVID-19 TherapyPivotal-lookingRecruiting
University of OxfordAcademic, hospital or other
NCT04381936 · 70,000 participants (planned) · Start Mar 19, 2020 · Primary completion Sep 30, 2028
Drug: Lopinavir-Ritonavir; Corticosteroid and 20 more · For: Pneumonia
Sites: Brussels, Belgium; Tallinn, Estonia; Paris, France · 16 sites in all
- Protective Effect, Safety and Immunogenicity of Live Attenuated Varicella Vaccine in Anhui ProvinceStatus unknown
Sinovac (Dalian) Vaccine Technology Co., Ltd.Industry
NCT05470855 · 45,400 participants (planned) · Start Jul 6, 2022 · Primary completion Nov 30, 2022
Drug: Live attenuated varicella vaccine · For: Varicella
Sites: Anqing, China; Chuzhou, China; Fuyang, China · 5 sites in all
- Crystalloid FLUID Choices for Resuscitation of Hospitalized PatientsPivotal-lookingCompleted
Ottawa Hospital Research InstituteAcademic, hospital or other
NCT04512950 · 43,626 participants · Start Aug 15, 2016 · Primary completion Jun 13, 2020
Drug: Ringer's lactate; 0.9% saline · For: Fluid Therapy
Sites: Hamilton, Canada; London, Canada; Ottawa, Canada · 7 sites in all
- Tranexamic Acid to Prevent Heavy Bleeding After Childbirth in Women at Higher RiskPivotal-lookingRecruiting
London School of Hygiene and Tropical MedicineAcademic, hospital or other
NCT05562609 · 40,000 participants (planned) · Start Apr 22, 2024 · Primary completion Sep 2027
Drug: Tranexamic acid · For: Postpartum Hemorrhage
Sites: Mbeya, Tanzania
- A Global Phase III Clinical Trial of Recombinant COVID- 19 Vaccine (Sf9 Cells)Pivotal-lookingCompleted
WestVac Biopharma Co., Ltd.Industry
NCT04904471 · 39,663 participants · Start Jun 15, 2021 · Primary completion Jan 31, 2022
Drug: Recombinant COVID-19 vaccine (Sf9 cells) · For: COVID-19
Sites: Bekasi, Indonesia; Malang, Indonesia; Surabaya, Indonesia · 24 sites in all
Sinovac (Dalian) Vaccine Technology Co., Ltd.Industry
NCT05460429 · 37,920 participants (planned) · Start Jul 30, 2022 · Primary completion Mar 15, 2023
Drug: Live attenuated varicella vaccine · For: Varicella
Sites: Chuzhou, China; Lishui, China; Quzhou, China
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- dyspnoea8,061
- diarrhoea8,018
- nausea7,739
- fatigue7,639
- death5,524
- pneumonia5,333
- headache5,007
- asthenia4,954
- dizziness4,843
- vomiting4,824
- pain4,745
- off label use4,585
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 1,078 |
| 2005 | 2,073 |
| 2006 | 1,676 |
| 2007 | 1,948 |
| 2008 | 2,738 |
| 2009 | 3,164 |
| 2010 | 2,846 |
| 2011 | 3,378 |
| 2012 | 4,400 |
| 2013 | 2,965 |
| 2014 | 3,542 |
| 2015 | 5,860 |
| 2016 | 6,539 |
| 2017 | 6,288 |
| 2018 | 7,063 |
| 2019 | 7,001 |
| 2020 | 6,416 |
| 2021 | 6,262 |
| 2022 | 7,176 |
| 2023 | 7,145 |
| 2024 | 7,853 |
| 2025 | 7,866 |
| 2026 | 5,292 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Klor-Con (Potassium Chloride)
2024 spending
$9.7M
Beneficiaries
29,332
59,825 claims
Per beneficiary
$330
$2.55 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $12,836,107 |
| 2021 | $9,922,011 |
| 2022 | $10,154,459 |
| 2023 | $10,901,488 |
| 2024 | $9,689,568 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Fluid resuscitation with balanced electrolyte solutions results in faster resolution of diabetic ketoacidosis than with 0.9% saline in adults - A systematic review and meta-analysis.
Szabó GV, Szigetváry C, Turan C, et al. · Diabetes Metab Res Rev 2024 · Meta-Analysis, Systematic Review
- Intravenous Calcium to Decrease Blood Loss During Intrapartum Cesarean Delivery: A Randomized Controlled Trial.
Ansari JR, Yarmosh A, Michel G, et al. · Obstet Gynecol 2024 · Randomized Controlled Trial, Equivalence Trial
- Efficacy and safety of isotonic versus hypotonic intravenous maintenance fluids in hospitalized children: an updated systematic review and meta-analysis of randomized controlled trials.
Amer BE, Abdelwahab OA, Abdelaziz A, et al. · Pediatr Nephrol 2024 · Meta-Analysis, Systematic Review
- Resuscitation with blood products in patients with trauma-related haemorrhagic shock receiving prehospital care (RePHILL): a multicentre, open-label, randomised, controlled, phase 3 trial.
Crombie N, Doughty HA, Bishop JRB, et al. · Lancet Haematol 2022 · Clinical Trial, Phase III, Multicenter Study
- Antimicrobial dressings for the prevention of surgical-site infection: systematic review and meta-analysis.
Yusuf SM, James J, Chong B, et al. · Br J Surg 2026 · Systematic Review, Meta-Analysis
- Vinyl chloride exposure and cirrhosis: a systematic review and meta-analysis.
Frullanti E, La Vecchia C, Boffetta P, et al. · Dig Liver Dis 2012 · Meta-Analysis, Research Support, Non-U.S. Gov't
Sponsor: Upsher Smith Labs
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.